Printed from https://ideas.repec.org/s/spr/pharmo.html
Content
March 2025, Volume 9, Issue 2
- 161-178 Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations
by Praveen Thokala & Henrique Duarte & Stuart Wright & Don Husereau & Isabelle Durand-Zaleski & Peter Lindgren & Roelien Postema & Gerardo Machnicki & Louis Garrison - 179-205 Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review
by Amr A. El-Sayed & Nancy S. Bolous - 207-215 What Does Pharmaceutical 3D Printing Cost? A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency
by Sejad Ayyoubi & Liesbeth Ruijgrok & Hugo Kuy & Renske Ham & Frederick Thielen - 217-229 Economic Evaluation of Total Knee Replacement Compared with Non-Surgical Management for Knee Osteoarthritis in India
by Amatullah Sana Qadeer & Ananda Meher & Jennifer Rachel & Winnie Paulson & Abhilash Patra & Naline Gandhi & Nirupama AY & Lipika Nanda & Sarit Kumar Rout & Ambarish Dutta - 231-245 The Association between COVID-19 Status and Economic Costs in the Early Stages of the COVID-19 Pandemic: Evidence from a UK Symptom Surveillance Digital Survey
by Sung Wook Kim & Caterina Alacevich & Catia Nicodemo & Raphael Wittenberg & Simon Lusignan & Stavros Petrou - 247-257 Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data
by Alison D. Griffiths & Robert O. Young & Yong Yuan & Mohammad A. Chaudhary & Adam Lee & Jason Gordon & Philip McEwan - 259-270 Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium
by Kristof Theys & Sofie Vermander & Lieven Annemans & Christophe De Block & Michel P. Hermans & Imke Matthys & Frank Nobels & Trung Nguyen & Vanessa Preumont & Katerina Zakrzewska & Frank Vanderdonck - 271-282 Comparing Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patients’ Characteristics, Unmet Needs, and the Impact on Quality of Life and Costs in Germany
by Moritz Platen & Wolfgang Hoffmann & Bernhard Michalowsky - 283-290 Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis
by F. S. Mennini & A. Marcellusi & P. Sciattella & M. Scortichini & Angela Ragonese & F. Cattel & R. D’Antona & L. Mastro & S. Gori & G. Perrone & R. Migliorini & M. Trabucco Aurilio - 291-300 Clinical Complications and Healthcare Resource Utilization Associated with Conventional Management of Sickle Cell Disease with Recurrent Vaso-occlusive Crises and Transfusion-Dependent β-Thalassemia in Germany
by Chuka Udeze & Nanxin Li & Colin Kunzweiler & Jessica Baldwin & Petra Tuzin & Sebastian Dietmar Zingel & Céline Vetter & Silvia Dombrowski & Elena Georgiadou-Schmidt & Aranzazu Alba & Roland Meisel - 301-312 Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England
by Vasileios Kontogiannis & Farai Goromonzi & Brigitte Both & Frank Semrau & Michael Branagan-Harris & Jowan Atkinson & Paul R. Roberts & Mehdi Javanbakht - 313-326 From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment
by Lucrezia Ferrario & Barbara Menzaghi & Giuliano Rizzardini & Alessandro Roccia & Elisabetta Garagiola & Daniele Bellavia & Fabrizio Schettini & Emanuela Foglia - 327-327 Correction: From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment
by Lucrezia Ferrario & Barbara Menzaghi & Giuliano Rizzardini & Alessandro Roccia & Elisabetta Garagiola & Daniele Bellavia & Fabrizio Schettini & Emanuela Foglia - 329-329 Correction: Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data
by Anna Philipson & Lars Hagberg & Liselotte Hermansson & Jan Karlsson & Emma Ohlsson-Nevo & Linda Ryen
January 2025, Volume 9, Issue 1
- 5-13 Costs of Illness for Huntington’s Disease: A Systematic Review
by Divya Patil & Emily F. Gorman & T. Joseph Mattingly - 15-25 Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis
by Wendy I. Sligl & Charles Yan & Jeff Round & Xiaoming Wang & Justin Z. Chen & Cheyanne Boehm & Karen Fong & Katelynn Crick & Míriam Garrido Clua & Cassidy Codan & Tanis C. Dingle & Connie Prosser & Guanmin Chen & Alena Tse-Chang & Daniel Garros & David Zygun & Dawn Opgenorth & John M. Conly & Christopher J. Doig & Vincent I. Lau & Sean M. Bagshaw - 27-39 Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing Analysis
by Rachel Houten & Mohammad Iqbal Hussain & Antony P. Martin & Nick Ainsworth & Claudia Lameirinhas & Alexander W. Coombs & Simon Toh & Christopher Rao & Edward St John - 41-56 Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study
by Aren Fischer & Stephen Mac & Erica Stivelman Freiman & John K. Marshall & Kim Rand & Juan M. Ramos-Goñi - 57-68 Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland
by Mikko Kosunen & Jarno Ruotsalainen & Alvar Kallio & Roope Metsä & Paavo Raittinen & Leena Lehmus & Maarit J. Korhonen & Timo Purmonen - 69-81 Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand
by Tanawan Kongmalai & Juthamas Prawjaeng & Phorntida Hadnorntun & Pattara Leelahavarong & Usa Chaikledkaew & Ammarin Thakkinstian & Varalak Srinonprasert - 83-92 Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis
by Zheng-Yi Zhou & Mark E. Bensink & Nisha C. Hazra & Chunyi Xu & Bruce Hendry & Claire C. Sharpe & Mo Zhou - 93-101 Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
by Dong-Won Kang & Patricio B. Lynn & Li Wang & Shouhao Zhou & Chan Shen - 103-113 CMS’s Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks
by Julie A. Patterson & Tyler D. Wagner & Rayan K. Salih & Gabri’el D. Shabazz & Jonathan D. Campbell - 115-124 Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy
by Chuka Udeze & Melania Dovizio & Chiara Veronesi & Luca Degli Esposti & Nanxin Li & Thi Xuan Mai Patricia Dang & Gian Luca Forni - 125-136 Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment
by Yan Chen & Ella X. Du & Manasvi Sundar & Keith A. Betts & Xin Yin & Samantha Eiffert & Karen Beauchamp & Andrew Delgado & Lisa Rosenblatt - 137-145 Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years
by Eline H. Ploumen & Martijn J. Oude Wolcherink & Rosaly A. Buiten & Tineke H. Pinxterhuis & Carine J. M. Doggen & Carl E. Schotborgh & Peter W. Danse & Martijn Scholte & K. Gert Houwelingen & Paolo Zocca & Xavier G. L. V. Pouwels & Clemens Birgelen - 147-160 Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing
by Mussab Fagery & Hadi A. Khorshidi & Stephen Q. Wong & Özge Karanfil & Jon Emery & Maarten J. IJzerman
November 2024, Volume 8, Issue 6
- 787-792 Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of Life
by Ellen Kim DeLuca & Ann Chen Wu & Kurt D. Christensen & Davene R. Wright & Jennifer Yeh & Hadley Stevens Smith - 793-808 A Systematic Review of the Impact of Spinal Cord Injury on Costs and Health-Related Quality of Life
by Modou Diop & David Epstein - 809-822 Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore
by Clarence Ong & Jamaica Briones & Zhi Zhen Lim & Nisha Suyien Chandran & Haur Yueh Lee & Benny Kaihui Li & Yik Weng Yew & Hwee-Lin Wee - 823-836 Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses
by Fatemeh Mirzayeh Fashami & Jean-Eric Tarride & Behnam Sadeghirad & Kimia Hariri & Amirreza Peyrovinasab & Mitchell Levine - 837-845 Economic Impact of Bladder Cancer in the USA
by Otavio Clark & Tulio Sarmento & Anthony Eccleston & Julia Brinkmann & Renato Picoli & Vamsi Daliparthi & Jorine Voss & Sanjana Chandrasekar & Allison Thompson & Jane Chang - 847-856 Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
by Matilde Slot & Thomas Bøjer Rasmussen & Mette Nørgaard & Carsten Schade Larsen & Lars Holger Ehlers - 857-867 Clinicians’ Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment
by Alexander Keenan & Chiara Whichello & Hoa H. Le & David M. Kern & Gabriela S. Fernandez & Vicky Turner & Anup Das & Matt Quaife & Amy Perrin Ross - 869-885 Estimation of the Clinical, Economic, and Social Burden of Stage IV Non-Small Cell Lung Cancer in Mexico
by Denisse Añorve Bailon & Javier Picó-Guzmán & Sergio Cifuentes & Rogelio Trejo & Jeronimo Rodríguez Cid & Juan Jose Juarez-Vignon Whaley & Alan Alexis Heredia Zepeda & Raquel Gerson & Christian Patricio Camacho-Limas & José Fabián Martínez-Herrera & Diana Bonilla Molina & Efraín Camarín Sánchez & Daniela Shveid Gerson - 887-896 Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain
by Sergio Cedillo & Almudena González-Domínguez & Yoana Ivanova-Markova & Rafael López López & Sara López-Tarruella Cobo & José Alberto Peña Pedrosa - 897-909 Comparison of Two Financial Incentives to Encourage the Use of Adalimumab Biosimilars: Results of a French Experiment Close to Clinicians
by Marion Tano & Pascal Paubel & Matthieu Ribault & Albane Degrassat-Théas - 911-922 Estimating Australian Population Utilities for Inherited Retinal Disease Using Time Trade-Off
by Maria Farris & Stephen Goodall & Richard Abreu Lourenco & Brendan Mulhern & Kathleen Manipis & Elena Meshcheriakova & Milena Lewandowska - 923-934 Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK
by Danny Gibson & Neil Branscombe & Neil Martin & Andrew Menzies-Gow & Priya Jain & Katherine Padgett & Florian Yeates - 935-943 The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System
by Sam Harper & Muralikrishnan Kartha & Stuart Mealing & Maurizio Pavanello & Luigi Bonavina - 945-959 Artificial-Intelligence Cloud-Based Platform to Support Shared Decision-Making in the Locoregional Treatment of Breast Cancer: Protocol for a Multidimensional Evaluation Embedded in the CINDERELLA Clinical Trial
by Ludovica Borsoi & Elisabetta Listorti & Oriana Ciani - 961-961 Correction: Cost-Effectiveness of Dupilumab and Oral Janus Kinase Inhibitors for the Treatment of Moderate-to-Severe Atopic Dermatitis in Singapore
by Clarence Ong & Jamaica Briones & Zhi Zhen Lim & Nisha Suyien Chandran & Haur Yueh Lee & Benny Kaihui Li & Yik Weng Yew & Hwee-Lin Wee - 963-965 Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses
by Fatemeh Mirzayeh Fashami & Jean-Eric Tarride & Behnam Sadeghirad & Kimia Hariri & Amirreza Peyrovinasab & Mitchell Levine
September 2024, Volume 8, Issue 5
- 645-649 NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances
by Dawn Lee & Darren Burns & Ed Wilson - 651-664 Modeling First-Line Daratumumab Use for Newly Diagnosed, Transplant-Ineligible, Multiple Myeloma: A Cost-Effectiveness and Risk Analysis for Healthcare Payers
by Diana Beatriz Bayani & Yihao Clement Lin & Chandramouli Nagarajan & Melissa G. Ooi & Allison Ching Yee Tso & John Cairns & Hwee Lin Wee - 665-678 Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment
by Jürgen Wasem & Yanic Heer & Eleni Karamasioti & Erwan Muros-Le Rouzic & Giuseppe Marcelli & Danilo Maio & Stefan Braune & Gisela Kobelt & Paul Dillon - 679-688 Impact of Value-Driven Healthcare Strategies for Biosimilar Adoption: The Singapore Story
by She Hui Tan & Louise Gek Huang Goh & Benjamin Shao Kiat Ong & Darren Sze Guan Ng & Liang Lin & Raymond Chee Hui Ng & Bernard Yu-Hor Thong & Kwong Ng - 689-699 A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
by Paul Casabianca & Marc Massetti & François-Emery Cotte & Romain Moreau & Sarah Kassahun & Prianka Singh & Inkyu Kim & Anne-Françoise Gaudin & Guillaume Piessen & Henri Leleu - 701-714 Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy
by Jonathan Salcedo & Daniel Hill-McManus & Chloë Hardern & Oyin Opeifa & Raffaella Viti & Ludovica Siviero & Antonio Saverio Roscini & Gennaro Martino - 715-725 Psychometric Properties of the EQ-5D-5L in Patients with Alopecia Areata
by Andrew Lloyd & Daniel Aggio & Caleb Dixon & Ernest H. Law & Thomas Price - 727-738 Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina
by Natalia Espinola & Constanza Silvestrini & Carla Colaci & Daniela Sugg & Carlos Rojas-Roque & Jesica Coelli & Federico Augustovski - 739-753 A Cost Evaluation of COVID-19 Remote Home Monitoring Services in England
by Sonila M. Tomini & Efthalia Massou & Nadia E. Crellin & Naomi J. Fulop & Theo Georghiou & Lauren Herlitz & Ian Litchfield & Pei Li Ng & Chris Sherlaw-Johnson & Manbinder S. Sidhu & Holly Walton & Stephen Morris - 755-764 ENTIMOS: Decision Support Tool Highlights Potential Impact of Non-intravenous Therapies for Multiple Sclerosis on Patient Care via Clinical Scenario Simulation
by Richard Nicholas & Erik Scalfaro & Rachel Dorsey & Zuzanna Angehrn & Judit Banhazi & Roisin Brennan & Nicholas Adlard - 765-772 Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review
by Vittoria Ardito & Ludovico Cavallaro & Michael Drummond & Oriana Ciani - 773-781 Using a Patient-Centered Multicriteria Decision Analysis to Assess the Value of Multiple Sclerosis Treatments in the US: A Study Protocol
by Surachat Ngorsuraches & Tim C. Lai & Rebecca Habermann & Yolanda Wheeler & William Meador - 783-783 Correction: NICE’s Pathways Pilot: Pursuing Good Decision Making in Difficult Circumstances
by Dawn Lee & Darren Burns & Ed Wilson - 785-785 Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older
by Sydney George & Justin Carrico & Katherine A. Hicks & Dessi Loukov & Cheryl Ng & Jessica Regan & Nikolaos Giannelos
July 2024, Volume 8, Issue 4
- 507-510 Whither Decision-Analytic Modelling-Based Economic Evaluation for Health Care Decision Making?
by Rachael Maree Hunter & Matthew Franklin - 511-524 A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
by Sudewi Mukaromah Khoirunnisa & Fithria Dyah Ayu Suryanegara & Lisa Aniek Jong & Didik Setiawan & Maarten Jacobus Postma - 525-537 Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension
by Rod S. Taylor & Anthony Bentley & Kaylie Metcalfe & Melvin D. Lobo & Ajay J. Kirtane & Michel Azizi & Christopher Clark & Kieran Murphy & Jennifer H. Boer & Marjolijn Keep & An Thu Ta & Neil C. Barman & Garrett Schwab & Ron Akehurst & Roland E. Schmieder - 539-557 Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France
by Gérard Pouvourville & Manon Breau-Brunel & Véronique Loncle-Provot & Ekkehard Beck & Loïg Gaugain & Gaëlle Nachbaur & Céline Pribil - 559-568 Public Preference for Financing Preventive Vaccines in Health Shocks: The Case of COVID-19 Vaccines in a Middle-Income Country
by Najmeh Moradi & Leila Zarei & Narges Hajimoladarvish & Zahra Meshkani & Marzieh Zanganeh & Jafar Babapour & Kamran Bagheri Lankarani - 569-583 Evaluating the Long-Term Cost-Effectiveness of the English NHS Diabetes Prevention Programme using a Markov Model
by Emma McManus - 585-598 Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina
by Carlos Rojas-Roque & Constanza Silvestrini & Fernando Argento & Daniela Sugg & Federico Augustovski & Jesica Coelli & Natalia Espinola - 599-609 Cost of Care for Non-communicable Diseases: Which Types of Healthcare Providers are the Most Economical in India’s Chhattisgarh State?
by Samir Garg & Narayan Tripathi & Kirtti Kumar Bebarta - 611-626 A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales
by Colin Burke & Catriona Crossan & Emma Tyas & Matthew Hemstock & Dawn Lee & Sally Bowditch - 627-640 Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs
by Micha J. Pilz & Simone Seyringer & Imad Al-Naesan & Madeleine T. King & Andrew Bottomley & Richard Norman & Lisa Schlosser & Tobias Hell & Eva Maria Gamper - 641-641 Correction: Cost Effectiveness of Endovascular Ultrasound Renal Denervation in Patients with Resistant Hypertension
by Rod S. Taylor & Anthony Bentley & Kaylie Metcalfe & Melvin D. Lobo & Ajay J. Kirtane & Michel Azizi & Christopher Clark & Kieran Murphy & Jennifer H. Boer & Marjolijn Keep & An Thu Ta & Neil C. Barman & Garrett Schwab & Ron Akehurst & Roland E. Schmieder - 643-643 Correction: Developing a Natural History Model for Duchenne Muscular Dystrophy
by Jonathan Broomfield & M. Hill & F. Chandler & M. J. Crowther & J. Godfrey & M. Guglieri & J. Hastie & J. Larkindale & J. Mumby-Croft & E. Reuben & F. Woodcock & K. R. Abrams
May 2024, Volume 8, Issue 3
- 347-357 Introducing Open Science in Teaching Health Economic Modelling
by Xavier G. L. V. Pouwels & Hendrik Koffijberg - 359-371 Cost-Effectiveness of Routine Monitoring of Long-Term Conditions in Primary Care: Informing Decision Modelling with a Systematic Review in Hypertension, Type 2 Diabetes and Chronic Kidney Disease
by Syed G. Mohiuddin & Mary E. Ward & William Hollingworth & Jessica C. Watson & Penny F. Whiting & Howard H. Z. Thom - 373-387 Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany
by Niklaus Meier & Hendrik Fuchs & Katya Galactionova & Cedric Hermans & Mark Pletscher & Matthias Schwenkglenks - 389-401 Behind the Scenes: A Qualitative Investigation of Interviewers' Performance in EQ-5D Valuation Studies
by Carlotta Varriale & Giovanni Andrulli & Michela Meregaglia & Fanni Rencz & Aureliano Paolo Finch - 403-416 Cost-Effectiveness Analysis of Digital Breast Tomosynthesis Added to Synthetic Mammography in Breast Cancer Screening in Brazil
by Henrique Lima Couto & Ludmila Peres Gargano & Vilmar Marques Oliveira & Bertha Andrade Coelho & Eduardo Carvalho Pessoa & Augusto Tufi Hassan & Agnaldo Lopes Silva & Linei Augusta Brolini Delle Urban & Luciano Chala Fernandes & Nisha Sharma & Ritse Mann & Stuart A McIntosh & Fernando Zanghelini - 417-429 An Economic Evaluation of a Streamlined Day-Case Atrial Fibrillation Ablation Protocol and Conventional Cryoballoon Ablation versus Antiarrhythmic Drugs in a UK Paroxysmal Atrial Fibrillation Population
by Joe W. E. Moss & Derick Todd & Lukasz Grodzicki & Beatrice Palazzolo & Richard Mattock & Stuart Mealing & Maxim Souter & Benedict Brown & Tom Bromilow & Damian Lewis & James McCready & Muzahir Tayebjee & Ewen Shepherd & Thiagarajah Sasikaran & Clare Coyle & Eleni Ismyrloglou & Nicholas A. Johnson & Prapa Kanagaratnam - 431-443 Identification and prioritisation of items for a draft participant-reported questionnaire to measure use of social care, informal care, aids and adaptations
by Kirsty M. Garfield & Gail A. Thornton & Samantha Husbands & Ailsa Cameron & William Hollingworth & Sian M. Noble & Paul Roy & Joanna C. Thorn - 445-457 Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis
by Christian Bührer & Thomas Paling & Richard Gale & Tatiana Paulo & Marloes Bagijn - 459-469 Health-Related Quality of Life and Economic Burden Among Hospitalized Children with Hand, Foot, and Mouth Disease: A Multiregional Study in China
by Ting Zhou & Hongfei Hu & Junyang Gao & Hongjie Yu & Mark Jit & Pei Wang - 471-480 Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus
by Olga Pitsillidou & Panagiotis Petrou & M. J. Postma - 481-492 Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older
by Sydney George & Justin Carrico & Katherine A. Hicks & Dessi Loukov & Cheryl Ng & Jessica Regan & Nikolaos Giannelos - 493-505 A Canadian Simulation Model for Major Depressive Disorder: Study Protocol
by Shahzad Ghanbarian & Gavin W. K. Wong & Mary Bunka & Louisa Edwards & Sonya Cressman & Tania Conte & Sandra Peterson & Rohit Vijh & Morgan Price & Christian Schuetz & David Erickson & Linda Riches & Ginny Landry & Kim McGrail & Jehannine Austin & Stirling Bryan
March 2024, Volume 8, Issue 2
- 147-170 Health Economic Evaluations of Hemochromatosis Screening and Treatment: A Systematic Review
by Malvina Hoxha & Visar Malaj & Bruno Zappacosta - 171-190 A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma
by Fei Fei Liu & Meaghan Bartlett & Samantha Craigie - 191-203 Artificial Intelligence to Automate Health Economic Modelling: A Case Study to Evaluate the Potential Application of Large Language Models
by Tim Reason & William Rawlinson & Julia Langham & Andy Gimblett & Bill Malcolm & Sven Klijn - 205-220 Artificial Intelligence to Automate Network Meta-Analyses: Four Case Studies to Evaluate the Potential Application of Large Language Models
by Tim Reason & Emma Benbow & Julia Langham & Andy Gimblett & Sven L. Klijn & Bill Malcolm - 221-233 The Efficiency of Increased HCV Testing and Treatment Strategies in Spain to Achieve Elimination Goals
by Jose Luis Calleja & Jaime Espin & Ankita Kaushik & Manuel Hernandez-Guerra & Rob Blissett & Alon Yehoshua & Adam Igloi-Nagy - 235-249 Cost-Utility Analysis of Total Ankle Replacement Compared with Ankle Arthrodesis for Patients Aged 50–85 Years with End-Stage Ankle Osteoarthritis: The TARVA Study
by Andrew J. Goldberg & Ekaterina Bordea & Kashfia Chowdhury & Iva Hauptmannova & James Blackstone & Deirdre Brooking & Elizabeth L. Deane & Stephen Bendall & Andrew Bing & Chris Blundell & Sunil Dhar & Andrew Molloy & Steve Milner & Mike Karski & Steve Hepple & Malik Siddique & David T. Loveday & Viren Mishra & Paul Cooke & Paul Halliwell & David Townshend & Simon S. Skene & Caroline J. Doré - 251-261 From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
by Elvio Emanuele Rossini & Carlotta Galeone & Chiara Lucchetti & Claudio Jommi - 263-276 Health State Utilities Associated with False-Positive Cancer Screening Results
by Louis S. Matza & Timothy A. Howell & Eric T. Fung & Sam M. Janes & Michael Seiden & Allan Hackshaw & Lincoln Nadauld & Hayley Karn & Karen C. Chung - 277-289 Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden
by Maria Polyzoi & Mattias Ekman & Anja Reithmeier & Johanna Jacob & Emma Karlsson & Evelina Bertranou & Barbro Linderholm & Robert Hettle - 291-302 Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain
by Rosa María Romero Jiménez & Pedro Herranz Pinto & Minia Campos Domínguez & Susana Aceituno Mata & Alba Bellmunt & Miriam Prades & Daniel Arumi & Irene Hernández-Martín & Valeria Herrera-Lasso & Noelia Llevat & Alfonso Lossada Juste & Francisco José Rebollo Laserna - 303-311 An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund
by Laura A. Trigg & Maxwell S. Barnish & Samuel Hayward & Naomi Shaw & Louise Crathorne & Brad Groves & John Spoors & Thomas Strong & G. J. Melendez-Torres & Caroline Farmer - 313-331 Economic Evaluation of a Personalized Nutrition Plan Based on Omic Sciences Versus a General Nutrition Plan in Adults with Overweight and Obesity: A Modeling Study Based on Trial Data in Denmark
by Milanne Maria Johanna Galekop & Carin Uyl-de Groot & William Ken Redekop - 333-343 Understanding the Natural History of Chronic Hepatitis D: Proposal of a Model for Cost-Effectiveness Studies
by Ankita Kaushik & Geoffrey Dusheiko & Chong Kim & Nathaniel J. Smith & Csilla Kinyik-Merena & Gian Luca Tanna & Robert J. Wong - 345-345 Correction: From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
by Elvio Emanuele Rossini & Carlotta Galeone & Chiara Lucchetti & Claudio Jommi
January 2024, Volume 8, Issue 1
- 5-18 The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain
by Bérengère Macabeo & Théophile Rotrou & Aurélie Millier & Clément François & Philippe Laramée - 19-30 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
by Laurent Fauchier & Nicolas Lamblin & Jean Tardu & Lucile Bellier & Harinala Groyer & Deborah Ittah & Julien Chollet & Stephan Linden & Pierre Levy - 31-47 Specialist Palliative Care and Health Care Costs at the End of Life
by Patricia Kenny & Dan Liu & Denzil Fiebig & Jane Hall & Jared Millican & Sanchia Aranda & Kees Gool & Philip Haywood - 49-63 United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument
by Madeleine T. King & D. A. Revicki & R. Norman & F. Müller & R.C. Viney & A. S. Pickard & D. Cella & J. W. Shaw - 65-78 Preferences for Living Arrangements in Dementia: A Discrete Choice Experiment
by Christian Speckemeier & Carina Abels & Klemens Höfer & Anja Niemann & Jürgen Wasem & Anke Walendzik & Silke Neusser - 79-89 Developing a Natural History Model for Duchenne Muscular Dystrophy
by Jonathan Broomfield & M. Hill & F. Chandler & M. J. Crowther & J. Godfrey & M. Guglieri & J. Hastie & J. Larkindale & J. Mumby-Croft & E. Reuben & F. Woodcock & K. R. Abrams - 91-101 Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
by Andrea Favre-Bulle & Min Huang & Amin Haiderali & Arjun Bhadhuri - 103-114 Cost of Patients with Alzheimer’s Disease in Spain According to Disease Severity
by Laura Gómez Maldonado & Ricardo de Mora-Figueroa & Angélica López-Angarita & Paulina Maravilla-Herrera & María Merino - 115-118 Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates
by Jeremy Costin & Morgane C. Mouslim & Mariana P. Socal & Antonio Trujillo - 119-131 Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis
by Joost G. E. Verbeek & Karen Sluis & Marieke A. Vollebergh & Johanna W. Sandick & Wim H. Harten & Valesca P. Retèl - 133-146 Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)
by Hilary M. DuBrock & Hayley D. Germack & Marjolaine Gauthier-Loiselle & Jörg Linder & Ambika Satija & Ameur M. Manceur & Martin Cloutier & Patrick Lefebvre & Sumeet Panjabi & Robert P. Frantz
November 2023, Volume 7, Issue 6
- 863-875 Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
by Marty Chaplin & Rebecca Bresnahan & Nigel Fleeman & James Mahon & Rachel Houten & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Pinki Munot - 877-886 Characteristics and Quality Appraisal of the Economic Evaluations Done in Ethiopia: A Systematic Review
by Bereket Bahiru Tefera & Desalegn Getnet Demsie & Adane Yehualaw & Chernet Tafere & Kebede Feyisa & Malede Berihun Yismaw & Belayneh Kefale & Zewdu Yilma - 887-914 Cost-Effectiveness of Non-pharmacological Interventions for Mild Cognitive Impairment and Dementia: A Systematic Review of Economic Evaluations and a Review of Reviews
by Gillian Eaglestone & Evdoxia Gkaintatzi & Harmony Jiang & Charlotte Stoner & Rosana Pacella & Paul McCrone - 915-926 Trade-Offs between Vaccine Effectiveness and Vaccine Safety: Personal versus Policy Decisions
by Semra Ozdemir & Sean Ng & Vinh Anh Huynh & Axel Mühlbacher & Hiang Khoon Tan & Eric Andrew Finkelstein - 927-940 Hospital Resource Utilization and Costs in Patients with Heart Failure in France
by Frank Chemouni & Tiffany Chihiro Nishikawa & Harinala Groyer & Oumou Diaby & Julien Chollet & Deborah Ittah - 941-950 Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma
by Elisabeth F. P. Peterse & Elisabeth J. M. Verburg-Baltussen & Alexa Stewart & Fei Fei Liu & Christopher Parker & Maarten Treur & Bill Malcolm & Sven L. Klijn - 951-961 Budget Impact Analysis of Risperidone Use and Adverse Event Monitoring in Autism Spectrum Disorder in Brazil: Assessment of Theoretical Versus Real Data
by Luis Phillipe Nagem Lopes & Alexander Itria & Luciane Cruz Lopes - 963-974 The EQ-5D-3L Valuation Study in Pakistan
by Madeeha Malik & Ning Yan Gu & Azhar Hussain & Bram Roudijk & Fredrick Dermawan Purba - 975-985 Cost-Effectiveness of Recombinant Zoster Vaccine for the Prevention of Herpes Zoster in Hematopoietic Stem Cell Transplant Recipients and Other Immunocompromised Adults in the United States
by Ahmed Salem & Elizabeth M. La & Desmond Curran & Brandon J. Patterson & Justin Carrico & Stéphane Lorenc & Katherine A. Hicks & Sara Poston & Christopher F. Carpenter - 987-995 Estimating Cumulative Health Care Costs of Childhood and Adolescence Autism Spectrum Disorder in Ontario, Canada: A Population-Based Incident Cohort Study
by Claire Oliveira & Bryan Tanner - 997-1006 Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada
by Reka E. Pataky & Stirling Bryan & Mohsen Sadatsafavi & Stuart Peacock & Dean A. Regier - 1007-1013 Model and Empirical Data-Based Cost-Utility Studies of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Protocol of a Systematic Review on Methodology and Quality
by L. A. Jong & X. Li & S. Emamipour & S. Werf & M. J. Postma & P. R. Dijk & T. L. Feenstra - 1015-1015 Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
by Marty Chaplin & Rebecca Bresnahan & Nigel Fleeman & James Mahon & Rachel Houten & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Pinki Munot
September 2023, Volume 7, Issue 5
- 679-708 Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review
by Jorien Laermans & Hans Van Remoortel & Hans Scheers & Bert Avau & Jørgen Georgsen & Susan Nahirniak & Nadine Shehata & Simon J. Stanworth & Emmy De Buck & Veerle Compernolle & Philippe Vandekerckhove - 709-722 Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis
by Kenar D. Jhaveri & Mark E. Bensink & Martin Bunke & Jonathon A. Briggs & David M. W. Cork & Anushya Jeyabalan - 723-738 Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review
by Nick Jovanoski & Seye Abogunrin & Danilo Maio & Rossela Belleli & Pollyanna Hudson & Sneha Bhadti & Libby G. Jones - 739-750 Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England
by Tom Bromilow & Hayden Holmes & Laura Coote & Sam Woods & Joshua Pink - 751-764 Healthcare Costs at the End of Life for Patients with Non-cancer Diseases and Cancer in Denmark
by Anne Høy Seemann Vestergaard & Lars Holger Ehlers & Mette Asbjoern Neergaard & Christian Fynbo Christiansen & Jan Brink Valentin & Søren Paaske Johnsen - 765-776 Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data
by Anna Philipson & Lars Hagberg & Liselotte Hermansson & Jan Karlsson & Emma Ohlsson-Nevo & Linda Ryen - 777-792 Cost-Effectiveness Analysis of Siltuximab for Australian Public Investment in the Rare Condition Idiopathic Multicentric Castleman Disease
by Francis Shupo & Keith R. Abrams & Zanfina Ademi & Grace Wayi-Wayi & Natasa Zibelnik & Matt Kirchmann & Carolyn Rutherford & Kelly Makarounas-Kirchmann - 793-809 Perceptions and Attitudes Regarding Medical Device Development in Canada Among Canadian Innovators: A Qualitative Study
by Ikennah L. Browne & Andrew J. Sutton & Wei Zhang - 811-822 Disease Burden, Treatment Patterns, and Economic Impact of Rectovaginal Fistulas in Patients with Crohn’s Disease: Findings from a Retrospective, Observational, Longitudinal Study Based on US Claims Databases
by Chitra Karki & Dominick Latremouille-Viau & Inmaculada Gilaberte & Gary Hantsbarger & Hela Romdhani & Amy L. Lightner - 823-840 Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn’s Disease and Ulcerative Colitis
by Edward V. Loftus & Ashwin N. Ananthakrishnan & Wan-Ju Lee & Yuri Sanchez Gonzalez & Kristina A Fitzgerald & Kori Wallace & Wen Zhou & Leighann Litcher-Kelly & Sarah B. Ollis & Sylvia Su & Silvio Danese - 841-849 A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico
by Juan Carlos Garnica-Cuellar & Enrique Morales-Villegas & Carmen Alicia López-Forero & Bárbara Monroy-Cruz & Bhrugu Pariti & Swati Deshwal & Manisha Sekharan & Mariana Osorio-Hernández & Ida Caterina García-Appendini - 851-860 Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis
by Andrew Khair & Tray Brown & Marie Markert & Carsten Rødseth Barsøe & Gaurang S. Daftary & Patrick W. Heiser - 861-861 Correction: Cost-Effectiveness Analysis of Antimicrobial Prescribing in the Treatment of Clostridioides Difficile Infection in England
by Tom Bromilow & Hayden Holmes & Laura Coote & Sam Woods & Joshua Pink
July 2023, Volume 7, Issue 4
- 507-523 A Simple Cost-Effectiveness Model of Screening: An Open-Source Teaching and Research Tool Coded in R
by Yi-Shu Lin & James F O’Mahony & Joost Rosmalen - 525-536 Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rebecca Bresnahan & Rachel Houten & Janette Greenhalgh & Sarah Nevitt & James Mahon & Sophie Beale & Angela Boland & Devarshi Bhattacharyya & Yenal Dundar & Joanne McEntee & Shreyans Gandhi & Nigel Fleeman & Marty Chaplin - 537-552 Cost Effectiveness of Strategies for Caring for Critically Ill Patients with COVID-19 in Tanzania
by Hiral Anil Shah & Tim Baker & Carl Otto Schell & August Kuwawenaruwa & Khamis Awadh & Karima Khalid & Angela Kairu & Vincent Were & Edwine Barasa & Peter Baker & Lorna Guinness - 553-565 Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries
by Mackenzie Mills & Panos Kanavos - 567-577 Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
by Esra Çakar & César Oniangue-Ndza & Ralph P. Schneider & Sven L. Klijn & Ursula M. Vogl & Christian Rothermundt & Jessica R. May - 579-591 Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
by Ryan Pulleyblank & Nikolaj Birk Larsen - 593-603 Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing
by Fiona Koster & Marc R. Kok & Jaco Kooij & Geeke Waverijn & Angelique E. A. M. Weel-Koenders & Deirisa Lopes Barreto - 605-615 Secukinumab in Ankylosing Spondylitis Patients: A Cost-per-Responder Analysis from the Indonesian Health System Perspective
by Cesarius Singgih Wahono & Laniyati Hamijoyo & Yuriawati Hendrawan & Liyana Rakinaturia & Neha Mittal & Prabal Khanna & Minal Jain & Harry Isbagio - 617-626 Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis
by Julie Vanderpoel & Bruno Emond & Isabelle Ghelerter & Katherine Milbers & Marie-Hélène Lafeuille & Patrick Lefebvre & Lorie A. Ellis - 627-638 Estimation of Health Utility Scores for Glycogen Storage Disease Type Ia
by Eliza Kruger & Daniel Aggio & Hayley Freitas & Andrew Lloyd - 639-653 Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
by Megane Caillon & Benoit Brethon & Chrissy Beurden-Tan & Romain Supiot & Antoine Mezo & Jean-Vannak Chauny & Istvan Majer & Arnaud Petit - 655-663 Effect of Perioperative Oral Vitamin C Supplementation on In-Hospital Postoperative Medication Costs for Cardiac Surgery Patients: A Prospective, Single-Centre, Randomised Clinical Trial
by Jan Heerman & Charlotte Boydens & Silvie Allaert & Koen Cathenis & Koen Deryckere & Henk Vanoverschelde - 665-678 Systematic Review and Cost-Consequence Analysis of Ambu aScope 5 Broncho Compared with Reusable Flexible Bronchoscopes: Insights from Two US University Hospitals and an Academic Institution
by Anders E. Kristensen & Jonathan S. Kurman & D. K. Hogarth & Sonali Sethi & Sabrina S. Sørensen
May 2023, Volume 7, Issue 3
- 337-344 Unmet Parenthood Goals, Health-Related Quality of Life and Apparent Irrationality: Understanding the Value of Treatments for Infertility
by Chris Skedgel & Patricia Cubi-Molla & David Mott & Sofia Gameiro & Jacky Boivin & Hareth Al-Janabi & John Brazier & Marie Markert & Fredrik L. Andersson & Mireia Jofre-Bonet - 345-358 Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachel Houten & Nigel Fleeman & James Mahon & Marty Chaplin & Katherine Edwards & Sophie Beale & Angela Boland & Yenal Dundar & Ashley Marsden & Zafar Malik & Carlo Palmieri - 359-371 Health Economic Studies of Surfactant Replacement Therapy in Neonates with Respiratory Distress Syndrome: A Systematic Literature Review
by Tiziana Magni & Chiara Ragni & Nicola Pelizzi & Sheetal Sharma & Lucia Perez-Kempner & Erika Turkstra & Jyothsna Nathani & Martina Orlovic & Natalia Meshchenkova - 373-381 The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency
by Claudio Jommi & Carlotta Galeone - 383-392 Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067
by Taihang Shao & Mingye Zhao & Leyi Liang & Lizheng Shi & Wenxi Tang - 393-404 Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States
by Aryana Sepassi & Ila M. Saunders & Mark Bounthavong & Randy A. Taplitz & Cathy Logan & Jonathan H. Watanabe - 405-416 A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
by Paolo Angelo Cortesi & Carla Fornari & Paolo Gisondi & Florenzo Iannone & Ippazio Cosimo Antonazzo & Elisabetta Aloisi & Martina Fiocchi & Daniela Ritrovato & Lorenzo Giovanni Mantovani - 417-429 Economic Evaluation Comparing Virtual Reality with Child Life Programming for Non-sedated Pediatric Medical Imaging: A Cost-Consequence Analysis
by John Jacob & Chelsea Stunden & Dhayanand Deenadayalan & Luke Thomas - 431-441 Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain
by A. M. Alonso Torres & A. G. Arévalo Bernabé & N. Becerril Ríos & M. F. Hellín Gil & J. M. Martínez Sesmero & V. Meca Lallana & Ll. Ramió-Torrentà & A. Rodríguez-Antigüedad & L. Gómez Maldonado & I. Triana Junco & M. Gómez-Barrera & N. Espinoza Cámac & I. Oyagüez - 443-454 Economic Evaluation of Tirbanibulin for the Treatment of Actinic Keratosis in Scotland
by Amy Dymond & Will Green & Mary Edwards & Maria Angeles Lopez Pont & Girish Gupta - 455-467 Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer
by Andre Verhoek & Parneet Cheema & Barbara Melosky & Benoit Samson & Frances A. Shepherd & Filippo Marinis & Thomas John & Yi-Long Wu & Bart Heeg & Nadia Dalfsen & Benjamin Bracke & Miguel Miranda & Simon Shaw & Daniel Moldaver - 469-477 Elicitation of Health State Utilities Associated with Progression from Bacillus Calmette-Guerin (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC)
by Owen Alan Edwards Cooper & Ola Ghatnekar & Natalia Piglowska & Charlie A. Smith & Paul Swinburn & James W. F. Catto & Günter Niegisch & Jørn Skibsted Jakobsen - 479-491 Budget Impact of Three Improvement Targets for Compression Therapy for Patients with Deep Venous Thrombosis in The Netherlands
by Rachel H. P. Schreurs & Arina J. Cate-Hoek & Hugo Cate & Manuela A. Joore - 493-505 Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled Trial
by Charles Yan & Jeff Round & Ilke Akpinar & Chantal E. Atwood & Lesly Deuchar & Mohit Bhutani & Richard Leigh & Michael K. Stickland
March 2023, Volume 7, Issue 2
- 163-173 The Impact of Digital Health Interventions for the Management of Type 2 Diabetes on Health and Social Care Utilisation and Costs: A Systematic Review
by Tiyi Morris & Fiona Aspinal & Jean Ledger & Keyi Li & Manuel Gomes - 175-187 The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products
by Dawn Lee & Grant McCarthy & Omar Saeed & Rachel Allen & Kinga Malottki & Fleur Chandler - 189-197 Estimating the Incidence-Based Cost of Illness Due to Hematopoietic Stem Cell Transplantation Using One-Year Insurance Claim Data in Korea
by Sol Kwon & Hye-Young Kang - 199-216 A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
by Anuja Chatterjee & Gijs Wetering & Ron Goeree & Carolyn Owen & Anne Marie Desbois & Stephane Barakat & Beenish S. Manzoor & Kavita Sail - 217-228 Framework for Patient Experience Value Elements in Rare Disease: A Case Study Demonstrating the Applicability of Combined Qualitative and Quantitative Methods
by R. Brett McQueen & Nicholas D. Mendola & Ivett Jakab & Jeffrey Bennett & Kavita V. Nair & Bertalan Németh & András Inotai & Zoltán Kaló - 229-241 Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal
by Paulo Martins & Björn Vandewalle & Jorge Félix & Carlos M. Capela & João J. Cerqueira & António V. Salgado & Diana G. Ferreira & Isabel Monteiro - 243-255 A Budget Impact Model of Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with IgPro20 (Hizentra) Relative to Intravenous Immunoglobulin in the United States
by Rajiv Mallick & Rashad Carlton & Joris Stiphout - 257-271 Attributable Patient Cost of Antimicrobial Resistance: A Prospective Parallel Cohort Study in Two Public Teaching Hospitals in Ghana
by Evans Otieku & Ama Pokuaa Fenny & Appiah-Korang Labi & Alex Owusu Ofori & Joergen Anders Lindholm Kurtzhals & Ulrika Enemark - 273-284 Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China
by Shanlian Hu & Zhiliu Tang & James P. Harrison & Nadine Hertel & John R. Penrod & Jessica R. May & Ariadna Juarez-Garcia & Orban Holdgate - 285-298 Cost-Utility Analysis of the Caresyntax Platform to Identify Patients at Risk of Surgical Site Infection Undergoing Colorectal Surgery
by Eoin Moloney & Atefeh Mashayekhi & Mehdi Javanbakht & Mohsen Rezaei Hemami & Michael Branagan-Harris - 299-312 The Burden of Caring for Individuals with Tuberous Sclerosis Complex (TSC) Who Experience Epileptic Seizures: A Descriptive UK Survey
by Hanna Skrobanski & Kishan Vyas & Sally Bowditch & Lena Hubig & Edward Dziadulewicz & Louise Fish & Pooja Takhar & Siu Hing Lo - 313-320 A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America
by Aaron Winn & Anirban Basu & Scott D. Ramsey - 321-335 The Cost-Effectiveness of a Dance and Yoga Intervention for Girls with Functional Abdominal Pain Disorders
by Anna Philipson & Anna Duberg & Lars Hagberg & Sofie Högström & Lars Lindholm & Margareta Möller & Linda Ryen
January 2023, Volume 7, Issue 1
- 3-36 A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
by Conor McCloskey & María Toboso Ortega & Sunita Nair & Maria João Garcia & Federico Manevy - 37-46 Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
by F. Felizzi & Aino Launonen & P.-O. Thuresson - 47-48 Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
by F. Felizzi & Aino Launonen & P.-O. Thuresson - 49-62 Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
by Karan K. Shah & Melina Willson & Blaise Agresta & Rachael L. Morton - 63-63 Correction to: Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
by Karan K. Shah & Melina Willson & Blaise Agresta & Rachael L. Morton - 65-76 Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study
by Tetsuya Matsumoto & Akira Yuasa & Ryan Miller & Clive Pritchard & Takahisa Ohashi & Amer Taie & Jason Gordon - 77-91 “Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England
by Jiyeon Kang & John Cairns - 93-110 Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis
by Mehdi Javanbakht & Jesse Fishman & Eoin Moloney & Peter Rydqvist & Amir Ansaripour - 111-120 Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia
by Louisa G. Gordon & C. Wood & R. W. Tothill & P. M. Webb & P. Schofield & L. Mileshkin - 121-138 Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)
by Meryl Brod & Michael Højby Rasmussen & Suzanne Alolga & Jane F. Beck & Donald M. Bushnell & Kai Wai Lee & Aristides Maniatis - 139-148 Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the General Thai Population
by Krittaphas Kangwanrattanakul - 149-161 Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective
by François-Xavier Chalet & Teodora Bujaroska & Evi Germeni & Nizar Ghandri & Emilio T. Maddalena & Kushal Modi & Abisola Olopoenia & Jeffrey Thompson & Matteo Togninalli & Andrew H. Briggs
November 2022, Volume 6, Issue 6
- 773-786 Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification
by Matthew Fabbro & Kirah Hahn & Olivia Novaes & Mícheál Ó’Grálaigh & James F. O’Mahony - 787-797 The Cost of Flexible Bronchoscopes: A Systematic Review and Meta-analysis
by Carina Østervig Andersen & Helena Travis & Emilie Dehlholm-Lambertsen & Rasmus Russell & Emmelie Ploug Jørgensen - 799-809 Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis
by Keith B. Allen & James E. Alexander & Joshua N. Liberman & Susan Gabriel - 811-822 Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
by David Elsea & Lin Fan & Adela Mihai & Fadoua El Moustaid & Daniel Simmons & Matthew Monberg & Dominic Muston - 823-836 An EQ-5D-5L Value Set for Belgium
by Nicolas Bouckaert & Irina Cleemput & Stephan Devriese & Sophie Gerkens - 837-846 Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia
by Fabio Gil & Fabian Juliao-Baños & Luisa Amador & Natalia Castano & Juan Manuel Reyes - 847-857 What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care
by Megan Dale & Sarah F Bell & Susan O’Connell & Cerys Scarr & Kathryn James & Miriam John & Rachel E Collis & Peter W Collins & Grace Carolan-Rees - 859-870 Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
by Moogeh Baharnoori & Virender Bhan & Fraser Clift & Kimberly Thomas & Soukaïna Mouallif & Nicholas Adlard & Philip Cooney & François Blanchette & Barkha P. Patel & Daniel Grima - 871-880 Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months
by Andrew Blauvelt & Nianwen Shi & Russel Burge & Bilal Atiya & Baojin Zhu & Najwa Somani & Terri Ridenour & Carolyn R. Lew & Nicole M. Zimmerman & Mwangi J. Murage - 881-892 Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
by Holly Cranmer & David Trueman & Elise Evers & Fionn Woodcock & Tanja Podkonjak - 893-895 Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates
by Rachel Milstein Breslau & Joshua T. Cohen & Daniel A. Ollendorf & Peter J. Neumann - 897-897 Correction to: Implications of Payment for Acute Myocardial Infarctions as a 90-Day Bundled Single Episode of Care: A Cost of Illness Analysis
by Keith B. Allen & James E. Alexander & Joshua N. Liberman & Susan Gabriel - 899-899 Correction to: Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian Cancer
by David Elsea & Lin Fan & Adela Mihai & Fadoua El Moustaid & Daniel Simmons & Matthew Monberg & Dominic Muston
September 2022, Volume 6, Issue 5
- 631-635 Using Health Economics to Inform Immunization Policy Across All Levels of Government
by Ellen Rafferty & Laura Reifferscheid & Ali Assi & Shannon E. MacDonald - 637-646 How are Companion Diagnostics Considered in Economic Evaluations of Oncology Treatments? A Review of Health Technology Assessments
by Melissa Gomez Montero & Houcine El Alili & Mahmoud Hashim & Peter Wigfield & Mariya Dimova & Ralph Riley & Katie Pascoe